Adiponectin: Difference between revisions
CSV import Tag: Reverted |
No edit summary Tag: Manual revert |
||
| Line 40: | Line 40: | ||
{{hormone-stub}} | {{hormone-stub}} | ||
{{No image}} | {{No image}} | ||
Latest revision as of 16:45, 22 March 2025
Adiponectin is a protein hormone that is involved in regulating glucose levels as well as fatty acid breakdown. It is encoded by the ADIPOQ gene in humans. Adiponectin is produced and secreted by adipose tissue (fat cells) and is found in the bloodstream. It plays a crucial role in various metabolic processes, including glucose regulation and fatty acid oxidation.
Structure and Function[edit]
Adiponectin is a 244-amino acid protein that circulates in the blood in relatively high concentrations. It exists in multiple forms, including low-molecular-weight trimers, medium-molecular-weight hexamers, and high-molecular-weight multimers. The high-molecular-weight form is believed to be the most biologically active.
Adiponectin enhances the body's sensitivity to insulin, making it a key player in the management of type 2 diabetes. It also has anti-inflammatory properties and is involved in the suppression of metabolic derangements that may result in obesity, type 2 diabetes, atherosclerosis, and non-alcoholic fatty liver disease (NAFLD).
Mechanism of Action[edit]
Adiponectin exerts its effects by binding to specific receptors, known as adiponectin receptors (AdipoR1 and AdipoR2), which are widely distributed in various tissues, including the liver, skeletal muscle, and endothelial cells. Upon binding to these receptors, adiponectin activates several intracellular signaling pathways, including the AMP-activated protein kinase (AMPK) pathway and the peroxisome proliferator-activated receptor alpha (PPAR-α) pathway. These pathways play a significant role in enhancing insulin sensitivity and promoting fatty acid oxidation.
Clinical Significance[edit]
Low levels of adiponectin are associated with several metabolic disorders, including obesity, type 2 diabetes, cardiovascular disease, and metabolic syndrome. Conversely, higher levels of adiponectin are generally associated with a reduced risk of these conditions. Therefore, adiponectin is considered a potential therapeutic target for the treatment of metabolic diseases.
Research and Therapeutic Potential[edit]
Research is ongoing to develop therapies that can increase adiponectin levels or mimic its action. Such therapies could potentially be used to treat conditions like type 2 diabetes, obesity, and cardiovascular disease. Additionally, lifestyle interventions such as diet and exercise have been shown to increase adiponectin levels, thereby improving metabolic health.
See Also[edit]
- Adipose tissue
- Insulin resistance
- Type 2 diabetes
- Metabolic syndrome
- Cardiovascular disease
- Non-alcoholic fatty liver disease
- AMP-activated protein kinase
- Peroxisome proliferator-activated receptor alpha
References[edit]
<references group="" responsive="1"></references>
External Links[edit]
This hormone-related article is a stub. You can help WikiMD by expanding it.